On the 7th, our reporters received news from Harbin Medical University, revealing that a research team, led by Professors Zhou Qin and Cui Feiyun, has successfully developed a cutting-edge blood metabolite analysis and detection platform. This platform is a fusion of artificial intelligence, surface-enhanced Raman spectroscopy detection, and blood metabolite analysis technologies. By delving into the unique blood metabolite patterns associated with Alzheimer's disease, this platform not only ensures precise traceability of blood spectroscopy detection results but also uncovers potential interferences caused by non-standard pre-analytical handling of blood samples. Thus, it offers a groundbreaking technological approach for minimally invasive blood screening for Alzheimer's disease.

Leveraging AI algorithms, the platform constructs disease discrimination models that boast a classification accuracy rate surpassing 96%. Furthermore, it incorporates an innovative data matching algorithm that accurately links abnormal detection signals with specific alterations in blood metabolite concentrations. This advancement overcomes the long-standing technical challenge of non-traceability in traditional detection methods.

Moreover, the platform is capable of identifying the sources of detection errors, thereby facilitating the establishment of standardized operating procedures within the blood rapid testing industry. The related research findings have been published in an esteemed international journal, marking a significant milestone in the field of Alzheimer's disease research.